Novartis introduces Lucentis® in state of the art pre-filled syringe
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which received European approval in October 2013, is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 24, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Ophthalmology Latest News Source Type: news

Novartis Launches Lucentis In Intraocular Injection
Novartis announced it is launching Lucentis (ranibizumab) in pre-filled syringe (PFS) formulation designed for intraocular injection in Germany. The product will be launched in other markets throughout this year. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 21, 2014 Category: Pharmaceuticals Source Type: news

Ranibizumab Treatment for Neovascular AMDRanibizumab Treatment for Neovascular AMD
Are there risk factors for being a 'reduced responder' to ranibizumab treatment for AMD, and if so, what should clinicians be aware of? BMC Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 26, 2014 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news

Japanese authorities approve fourth indication for Genentech-Novartis' eye drug Lucentis
The Japanese regulatory bodies have approved Lucentis (ranibizumab) for a fourth indication for treatment of patients with diabetic macular edema (DME), a major cause of vision loss among diabetic patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 25, 2014 Category: Pharmaceuticals Source Type: news

Ranibizumab and Long-Term Diabetic Macular Edema OutcomesRanibizumab and Long-Term Diabetic Macular Edema Outcomes
The benefits of individualized ranibizumab treatment for diabetic macular edema (DME) persist for at least three years, according to results from the RESTORE extension study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 17, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Bevacizumab vs Ranibizumab: Cost-Effectiveness for AMDBevacizumab vs Ranibizumab: Cost-Effectiveness for AMD
Bevacizumab is more cost-effective than ranibizumab for the treatment of newly diagnosed neovascular macular degeneration, according to a mathematical model. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 14, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Developments in the treatment of AMD
Eylea (aflibercept) is a new anti-vascular endothelial growth growth factor inhibitor that is as effective and safe as ranibizumab in the treatment of neovascular age-related macular degeneration (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 14, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news

Aerpio doses first patient in Phase II trial of diabetic macular edema drug AKB-9778
US-based clinical-stage biopharmaceutical firm Aerpio Therapeutics has dosed the first patient in a Phase II trial designed to evaluate AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for treatment of diabetic macular… (Source: Drug Development Technology)
Source: Drug Development Technology - February 14, 2014 Category: Pharmaceuticals Source Type: news

Roche delivers strong 2013 results
Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics sales up 4% on strong Professional Diagnostics performance (Source: Roche Investor Update)
Source: Roche Investor Update - January 30, 2014 Category: Pharmaceuticals Source Type: news

AMD: Gene Variants Predict Response to Anti-VEGF DrugAMD: Gene Variants Predict Response to Anti-VEGF Drug
Minor alleles of the vascular endothelial growth factor 2 receptor gene predict response to ranibizumab treatment for wet AMD. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Ranibizumab for AMD: Dose and FrequencyRanibizumab for AMD: Dose and Frequency
The HARBOR study compared the efficacy and safety of 2 doses and 2 injection frequencies in patients with age-related macular degeneration. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2013 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Ranibizumab With and Without Ketorolac Eyedrops for AMDRanibizumab With and Without Ketorolac Eyedrops for AMD
Is ranibizumab more effective with or without the addition of ketorolac eyedrops in the treatment of exudative AMD? This new study takes a look. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 30, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

NICE says yes to Lucentis for myopic CNV in fast tracked draft final guidance
In a Final Appraisal Determination (FAD) published October 25, The National Institute for Health and Care Excellence (NICE) has recommended that Lucentis® (ranibizumab) be approved for use within the NHS in England and Wales as an option to treat people with visual impairment due to choroidal neovascularisation associated with pathological myopia (myopic CNV)6. Myopic CNV is the growth of abnormal leaky blood vessels in the back of the eye in high myopia (severe near sightedness)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 28, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news

Laser Reduces Retreatment in Diabetic Macular EdemaLaser Reduces Retreatment in Diabetic Macular Edema
Laser therapy added to ranibizumab significantly reduced the need for injections in patients with diabetic macular edema. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Cancer drug can treat blindness finds HTA funded research
A cheap cancer drug is just as effective and safe in treating a common cause of loss of vision as an expensive alternative, finds research funded by the NIHR Health Technology Assessment (HTA) Programme. The two year study, which published its results in The Lancet, compared anti-cancer drug Avastin (bevacizumab) with Lucentis (ranibizumab), the drug... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - September 26, 2013 Category: American Health Source Type: news